Ingrezza (valbenazine) is a prescription drug that’s used to treat certain movement disorders. The drug comes as an oral capsule. It’s usually taken once per day. Specifically, Ingrezza is used in ...

SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that a new analysis of INGREZZA ® (valbenazine) capsules, published in the Journal of Affective ...

Neurocrine Biosciences recently reported real-world claims data showing that adults with tardive dyskinesia treated with INGREZZA stayed on therapy longer and switched less often than matched patients ...

Last year, Neurocrine’s Ingrezza failed a phase 2 trial in pediatric Tourette Syndrome patients, prompting the company to use what it learned in designing a new phase 2b. But now Ingrezza has flunked ...

Credit: Neurocrine Biosciences. Nearly half of patients receiving Ingrezza saw a more than 40% reduction in Huntington disease chorea severity by the end of the treatment period. The Food and Drug ...

While 2017 saw the entrance of the first two drugs for tardive dyskinesia, the percentage of TD patients who are actually diagnosed remains in the single digits. Neurocrine is looking to change that ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Ingrezza sprinkle capsules to treat adults with Huntington’s disease chorea or tardive ...

Neurocrine Biosciences has successfully diversified beyond Ingrezza, with Crenessity's rapid adoption validating its multi-franchise commercial strategy. NBIX's late-stage neuropsychiatry pipeline, ...

Neurocrine Biosciences is a pharmaceutical company specializing in the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company recently submitted a proposal for the use ...

SAN DIEGO, Nov. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that INGREZZA ® (valbenazine) capsules, the first FDA approved product indicated for the treatment ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX) stock is trading higher on Tuesday after the company reported better-than-expected first-quarter 2025 earnings. The company on Monday reported adjusted EPS of ...